scholarly journals Risk factors for multiple drug resistant tuberculosis relapses

2020 ◽  
Vol 98 (11) ◽  
pp. 21-26
Author(s):  
А. S. Аlliluev ◽  
O. V. Filinyuk ◽  
E. E. Shnayder ◽  
P. N. Golubchikov ◽  
D. E. Аmichba
Keyword(s):  
Risk Factors ◽  
Medical Center ◽  
Multiple Drug ◽  
Sputum Smear ◽  
Smear Microscopy ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Multiple Drug Resistant ◽  
Mdr Tb

The objective of the study: to identify risk factors for relapses in patients after the effective course of chemotherapy for multiple drug resistant tuberculosis (MDR TB). Subjects and methods. Medical files of 346 adult MDR TB patients were analyzed, they all had the effective treatment as per regimen IV in Tomsk Phthisiopulmonology Medical Center in 2009-2011. They were divided into 2 groups: Group 1 included 35 patients who developed a relapse of tuberculosis over the next 5 years; Group 2 consisted of 311 patients who had no relapse of the disease over the next 5 years. Results. The relapse rate in effectively treated MDR TB patients made 10.1% (35/346 patients). The following social factors contributed to higher chances of the relapse: retirement age (p = 0.045; OR = 2.86 [1.14-7.20]) and disability due to somatic diseases (p < 0.001; OR = 4.82 [2.13-10.90]); while biomedical factors were the following: HIV infection (OR = 19.19 [5.29-69.56]), mental illness (OR = 5.85 [2.27-15.03]), tobacco smoking (OR = 3.16 [1.08-9.20]). People with history of tuberculosis relapses (OR = 12.17 [4.19-35.34]) have higher chances of relapse, as well as those having the following characteristics of the tuberculosis disease during the effective chemotherapy course: destruction of lung tissue (OR = 7.48 [1.76-31.80]), positive results of sputum smear microscopy (OR = 2.91 [1.28-6.61]), persisting bacterial excretion (by culture) after 2 months of chemotherapy (OR = 4.98 [2.41-10.29]).

scholarly journals Machine Learning for Prediction of Relapses in Multiple Drug Resistant Tuberculosis Patients

2021 ◽  
Vol 99 (11) ◽  
pp. 27-34
Author(s):  
A. S. Аlliluev ◽  
O. V. Filinyuk ◽  
E. E. Shnаyder ◽  
S. V. Аksenov
Keyword(s):  
Machine Learning ◽  
Learning Algorithms ◽  
Machine Learning Algorithms ◽  
Gradient Boosting ◽  
Multiple Drug ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Multiple Drug Resistant ◽  
Mdr Tb

The objective of the study: to evaluate the possibility of using machine learning algorithms for prediction of relapses in multiple drug resistant tuberculosis (MDR TB) patients.Subjects and Methods. Сlinical, epidemiological, gender, sex, social, biomedical parameters and chemotherapy parameters were analyzed in 346 cured MDR TB patients. The tools of the scikit-learn library, Version 0.24.2 in the Google Colaboratory interactive cloud environment were used to build forecasting models.Results. Analysis of the characteristics of relapse prediction models in cured MDR TB patients using machine learning algorithms including decision tree, random forest, gradient boosting, and logistic regression using K-block stratified validation revealed high sensitivity (0.74 ± 0.167; 0.91 ± 0.17; 0.91 ± 0.14; 0.91 ± 0.16, respectively) and specificity (0.97 ± 0.03; 0.98 ± 0.02; 0.98 ± 0.02; 0.98 ± 0.02, respectively).Five main predictors of relapse in cured MDR-TB patients were identified: repeated courses of chemotherapy; length of history of tuberculosis; destructive process in the lungs; total duration of treatment less than 22 months; and use of less than five effective anti-TB drugs in the regimen of chemotherapy.

scholarly journals Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran

2005 ◽  
Vol 9 (6) ◽  
pp. 317-322 ◽  
Author(s):  
Seyed Mehdi Mirsaeidi ◽  
Payam Tabarsi ◽  
Kaveh Khoshnood ◽  
Majid Valiollah Pooramiri ◽  
Ali Rowhani-Rahbar ◽  
...  
Keyword(s):  
Multiple Drug ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Multiple Drug Resistant ◽  
Mdr Tb

scholarly journals Safety of treatment regimens in multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019

2020 ◽  
Vol 98 (1) ◽  
pp. 5-15
Author(s):  
D. A. Ivanova ◽  
S. E. Borisov ◽  
O. V. Rodina ◽  
A. V. Filippov ◽  
T. N. Ivanushkina ◽  
...  
Keyword(s):  
Risk Factors ◽  
World Health ◽  
Multiple Drug ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Treatment Regimens ◽  
Resistant Tuberculosis ◽  
Multiple Drug Resistant ◽  
Group A ◽  
Health Organization

The objective: safety assessment of chemotherapy regimens compiled in accordance with the recommendations of World Health Organization (WHO), 2019, in patients with multiple drug resistant tuberculosis (MDR) in clinical practice settings.Subjects: Frequency, patterns, severity and risk factors of adverse events (AE) of chemotherapy regimens compiled in accordance with the WHO recommendations as of 2019 were analyzed in 122 patients with MDR and XDR respiratory tuberculosis within programmatic use of new anti-tuberculosis drugs.Results. The frequency of AE made 64.8% (95% CI 55.9-72.7%), gastrointestinal, cardiovascular and allergic events prevailed, the comorbidity was the risk factor of AE development (OR 6.44; 95% CI 1.91-21.76). AEs of with severity degrees 3-4 were observed in 24.6% (95% CI 17.8-33.0%), neurotoxic, ototoxic and hepatotoxic reactions prevailed; risk factors included female sex (OR 3.15, 95% CI 1.32-7.53) and complications of chemotherapy in the past (OR 3.50%, 95% CI 1.49-8.70). At least one anti-tuberculosis drug was canceled due to AE in 26.2% (95% CI 19.2-34.7%), and any of Group A drugs was canceled during the first 6 months of chemotherapy in 13.9% (95% CI 8.8-21.3%) of patients.

scholarly journals OTOTOXICITY IN MDR-TB PATIENTS ON CATEGORY-4 REGIMEN: A CASE REPORT

2020 ◽  
Vol 7 (2) ◽  
pp. 257-259
Author(s):  
Tanish Baqar ◽  
Sharique Ahmad ◽  
Silky Rai
Keyword(s):  
Case Report ◽  
Large Scale ◽  
Multiple Drug Resistance ◽  
Multiple Drug ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Medical Progress ◽  
Resistant Tuberculosis ◽  
Multiple Drug Resistant ◽  
Mdr Tb

Multiple drug-resistant tuberculosis (MDR-TB) is a critical situation affecting adults as properly as children across the globe (1). To determine the incidence and risk factors associated with Multiple Drug Resistant Tuberculosis (MDR-TB) (2), we studied Ototoxicity on 18 culture confirmed MDR-TB patients in Eras' Lucknow Medical College and Hospital, Lucknow from September, 2019 to January, 2020. This case follows a well documented report of a patient describing an unusual and novel occurrence of ototoxicity when undergoing treatment concerning multiple drug resistance tuberculosis along with symptoms, signs, diagnosis, treatment and follow-up (3). For descriptive convenience, the patient will be classified as patient 1. The following case is the cornerstones of medical progress and provides many new ideas in medicine. Containing an extensive review of the relevant literature on the topic, the case report is a rapid short communication between busy clinicians who may not have time or resources to conduct large scale research.(4)

scholarly journals Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013–2018

2021 ◽  
Vol 18 (9) ◽  
pp. 4663
Author(s):  
Khasan Safaev ◽  
Nargiza Parpieva ◽  
Irina Liverko ◽  
Sharofiddin Yuldashev ◽  
Kostyantyn Dumchev ◽  
...  
Keyword(s):  
Risk Factors ◽  
Treatment Outcomes ◽  
Treatment Success ◽  
National Level ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Loss To Follow Up ◽  
Resistant Tuberculosis ◽  
Mdr Tb

Uzbekistan has a high burden of drug-resistant tuberculosis (TB). Although conventional treatment for multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) has been available since 2013, there has been no systematic documentation about its use and effectiveness. We therefore documented at national level the trends, characteristics, and outcomes of patients with drug-resistant TB enrolled for treatment from 2013–2018 and assessed risk factors for unfavorable treatment outcomes (death, failure, loss to follow-up, treatment continuation, change to XDR-TB regimen) in patients treated in Tashkent city from 2016–2017. This was a cohort study using secondary aggregate and individual patient data. Between 2013 and 2018, MDR-TB numbers were stable between 2347 and 2653 per annum, while XDR-TB numbers increased from 33 to 433 per annum. At national level, treatment success (cured and treatment completed) for MDR-TB decreased annually from 63% to 57%, while treatment success for XDR-TB increased annually from 24% to 57%. On multivariable analysis, risk factors for unfavorable outcomes, death, and loss to follow-up in drug-resistant TB patients treated in Tashkent city included XDR-TB, male sex, increasing age, previous TB treatment, alcohol abuse, and associated comorbidities (cardiovascular and liver disease, diabetes, and HIV/AIDS). Reasons for these findings and programmatic implications are discussed.

Sign in / Sign up

Export Citation Format

Share Document